Recent Evidence for Treatment Augmentation With Second-Generation Antipsychotics in Major Depressive Disorder
  • CME

Learn about the efficacy and role of second-generation antipsychotics for treatment augmentation in patients with MDD and learn how to mitigate and manage adverse events.
Rakesh Jain, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: May 7, 2020 Expiration: May 6, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the efficacy and safety of atypical antipsychotic therapies used to augment treatment of patients with MDD, especially in the setting of comorbidities such as cardiovascular disease
  • Develop patient-tailored treatment plans that include guideline-directed augmentation strategies to manage residual MDD symptoms

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Otsuka and Lundbeck Alliance

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Rakesh Jain, MD, MPH

Clinical Professor
Department of Psychiatry
Texas Tech Health Sciences Center, School of Medicine
Midland, Texas

Rakesh Jain, MD, MPH, has disclosed that he has received consulting fees from Acadia, Alfasigma, Alkermes, Allergan, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos, Neurocrine, Osmotica, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, and Teva; has received fees for non-CME services from Alkermes, Allergan, Ironshore, Janssen, Lilly, Lundbeck, Merck, Neos, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, and Tris; has received funds for research support from Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda; and that his spouse/partner has received consulting fees from Lilly, Otsuka, Pamlab, and Sunovion and fees for non-CME services from Lilly.

Staff

Katherine Kahn
Katherine Kahn has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended primarily for psychiatrists and primary care physicians who care for patients with MDD.

Goal

The goal of this activity is to improve the learners’ competence in selecting treatment augmentation modalities (eg, dosage changes, antidepressant switching, adding atypical antipsychotic) for patients with MDD who respond suboptimally to antidepressant therapy.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 07, 2020, through May 06, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Free slides from CCO and Rakesh Jain, MD, MPH: Expert insights on efficacy, role of antipsychotics in MDD, mitigating and manage adverse events

Rakesh Jain, MD, MPH Released: May 7, 2020

Free slides from CCO and Christoph U. Correll, MD: Expert insights on comorbidities in treatment augmentation for MDD

Christoph U. Correll, MD Released: April 13, 2020

Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO

Daniel R. Kuritzkes, MD Released: March 19, 2020

Celine Gounder, MD, ScM, FIDSA: how healthcare providers can be prepared for when coronavirus comes to them. Testing for COVID-19, symptoms, screening, from CCO

Celine Gounder, MD, ScM, FIDSA Released: March 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue